Secretory phospholipase A2-IIA targets bacterial extracellular vesicles to modulate immune signaling
Secretory phospholipase A<sub>2</sub>-IIA (sPLA<sub>2</sub>-IIA) is a bactericidal enzyme that hydrolyzes membrane phospholipids, releasing lipid metabolites that can affect inflammation. sPLA<sub>2</sub>-IIA exhibits poor activity toward eukaryotic cells but preferentially targets gram-positive bacterial membranes. While sPLA<sub>2</sub>-IIA is constitutively expressed in the intestine and upregulated by inflammation in various bodily fluids, its precise physiological substrates remain debated. Intriguingly, sPLA<sub>2</sub>-IIA can modulate the intestinal lipidome without altering the microbiota composition. Here, we investigated whether sPLA<sub>2</sub>-IIA could use membranes from bacterial extracellular vesicles (bEVs) as alternative substrates to modulate immune signaling. We found that bEVs from both Staphylococcus aureus and Escherichia coli could mitigate the bactericidal effects of sPLA<sub>2</sub>-IIA on gram-positive bacteria. Enzymatic hydrolysis of bacteria, bEVs and fecal extracellular vesicles released distinct lipid metabolites and differentially impacted Toll-like receptor activation. These findings suggest that sPLA<sub>2</sub>-IIA can use bEVs as substrates and modulate inflammatory signaling through the generation of pathogen-associated molecular patterns, thus linking bacterial lipid metabolism to host immune response.
Authors
- Sandra Isabel (ORCID: https://orcid.org/0000-0001-7277-4150)
- Satoshi Morozumi (ORCID: https://orcid.org/0000-0002-7997-9834)
- Jean‐François Bilodeau (ORCID: https://orcid.org/0000-0001-9427-5387)
- Valérie Chénard (ORCID: https://orcid.org/0000-0002-2073-1279)
- Isabelle Allaeys (ORCID: https://orcid.org/0000-0003-4697-046X)
- Iwona Rudkowska (ORCID: https://orcid.org/0000-0003-2392-564X)
- Nicolas Bertrand (ORCID: https://orcid.org/0000-0002-2568-3771)
- Éric Boilard (ORCID: https://orcid.org/0000-0001-6319-6432)
- Alain Brisson (ORCID: https://orcid.org/0000-0003-0342-352X)
- Ève Bérubé
- Étienne Doré (ORCID: https://orcid.org/0000-0002-2347-5012)
- Makoto Arita (ORCID: https://orcid.org/0000-0001-9902-0463)
- Maurice Boissinot (ORCID: https://orcid.org/0000-0002-9143-2188)
- Gérard Lambeau (ORCID: https://orcid.org/0000-0002-9239-518X)
- Karine Greffard (ORCID: https://orcid.org/0000-0003-4827-6228)
- Tania Lévesque
- G. Lemaire (ORCID: https://orcid.org/0009-0001-1760-7015)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Université de Bordeaux (FR)
- Keio University (JP)
- Centre hospitalier universitaire de Québec (CA)
- Hôtel-Dieu de Québec (CA)
- Chimie et Biologie des Membranes et des Nanoobjects (FR)
- Centre hospitalier de l'Université Laval (CA)
- RIKEN Center for Integrative Medical Sciences (JP)
- Institut Polytechnique de Bordeaux (FR)
- Institut de Pharmacologie Moléculaire et Cellulaire (FR)
- Université Laval (CA)
- Yokohama City University (JP)
Publication Details
- Journal
- Communications Biology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1038/s42003-025-09025-4
- Citations
- 1
- Primary Topic
- Bacterial Infections and Vaccines
- Type
- article
- Field-Weighted Citation Impact
- 1.18
Funders
- Université Laval
- Japan Agency for Medical Research and Development
- Centre Hospitalier Universitaire de Québec
- Fonds de Recherche du Québec - Santé
- Exploratory Research for Advanced Technology